IPM Take
Effective MS treatment must be judged across the whole patient, not only by disease control in the nervous system. The Swedish findings give clinicians a measurable inflammatory-bowel-disease signal for rituximab. They support informed choice and attention to symptoms, while leaving causation and the risk with other anti-CD20 medicines unresolved.
Executive Summary
The population-based study examined 13,748 treatment episodes among 9,251 people with relapsing-remitting MS. New inflammatory bowel disease occurred during 40 rituximab episodes and four episodes involving natalizumab, dimethyl fumarate or fingolimod. Crude incidence rates were approximately 110 and 13 per 100,000 person-years, respectively; the adjusted five-year number needed to harm for rituximab versus the grouped comparators was 131. The analysis was observational and had few events in the comparator group. It does not provide the same risk estimate for every anti-CD20 medicine.
Why it matters
- Patients: Persistent new bowel symptoms during treatment warrant assessment, and the possible risk belongs in shared treatment decisions.
- Clinicians: Monitoring should extend beyond relapses and neurological disability to adverse effects in other organ systems.
- Regulators: The study offers a population-level safety signal for continued evaluation, without establishing a class-wide causal effect.
- Payers: Comparative safety can affect the overall value of treatment, but a small absolute risk should be weighed against MS benefits.
The Swedish registry analysis in JAMA Neurology moves a possible gastrointestinal adverse effect beyond individual case reports. Researchers linked MS treatment records with health registers and compared rituximab episodes with episodes involving three other disease-modifying therapies. They found substantially more new inflammatory bowel disease during rituximab exposure, even after adjustment for measured differences at treatment start.
The absolute event count remains important. There were 40 cases during 6,481 rituximab episodes and four during 7,267 comparator episodes. Those figures justify attention, but treatment groups may differ in ways the analysis cannot fully account for. The study also examined rituximab specifically; it should not be presented as an equivalent risk estimate for ocrelizumab, ofatumumab or ublituximab.
The immediate care response is proportionate. Patients considering treatment can discuss the potential risk alongside expected MS control, while those developing persistent diarrhoea, abdominal pain or bleeding should receive appropriate evaluation. The findings do not support automatic withdrawal of effective therapy. Further comparisons will be needed to establish how much of the observed association is attributable to the treatment itself.

